Oncology

Treatment shows the potential to turn metastatic breast tumors into low-grade tumors.

Prognosis markers may help project clinical outcomes for CRC patients.

Study finds adoption of Medicaid expansion could reduce disparities in breast cancer screening.

A national community-level study of Medicare patients with advanced non-small cell lung cancer found that adding targeted therapy to chemotherapy regimens was not cost-effective.

Palbociclib has been found effective inhibiting the mobilization of enzymes that contribute to the rapid division of tumor cells.

Sprouty 2 gene works differently in colorectal cancer than in other types of cancers.

Research may lead to new treatment approach for cancer.

Combination of treatments may slow disease progression.

Top stories from last week in oncology drug development.

Keytruda acts by allowing T cells to recognize and attack cancer cells.

Researchers explore alternate treatment for chronic lymphocytic leukemia.

Top news of the week in cancer drug development.

A majority of bowel cancers could be classified into four major categories defined by the researchers.

Global AML market forecast to reach nearly a billion dollars by 2024.

Ibrutinib is significantly more effective than chlorambucil in chronic lymphocytic leukemia.

Researchers evaluate association between psoriasis and cancer.

Experimental tyrosine kinase inhibitor targets T790M mutation-positive non-small cell lung cancer.

Colon cancer in African Americans associated with more aggressive clinical behavior.

Although smoking is a well-known risk factor for lung cancer, the results of a recent study indicate that smokers with chronic obstructive pulmonary disease (COPD) face a significantly higher risk of developing lung cancer than smokers without the respiratory condition.

Latest developments in oncology drug research.

Hope on the horizon for patients with liver damage.

Revenue not expected to maintain pace of current immunology treatments.

Submission bolstered by trials evaluating biosimilar candidate in moderate-to-severe plaque psoriasis and rheumatoid arthritis.

Researchers evaluate link between hemoglobin and morbidity in patients who undergo major gastrointestinal surgery.

Severity and type of symptoms varies among cancer patients in different age groups.

Continued steroid use associated with worse anxiety, sleep, and fatigue.

Out-of-pocket costs to remain a significant hurdle for patients even after closing of coverage gap.

Vistogard treats patients who develop life-threatening toxicities within days of receiving cancer drugs.